Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2020-2030F

Description

The Global Next Generation Biotherapeutics (NGBT) Market was valued at USD 5.42 billion in 2024 and is projected to reach USD 10.75 billion by 2030, growing at a CAGR of 12.05%. NGBTs signify a transformative leap in biopharmaceutical innovation, utilizing advanced technologies such as gene therapy, cell therapy, RNA interference, and monoclonal antibodies to deliver precise and personalized treatment. These therapies are engineered to target specific disease mechanisms, improving treatment effectiveness while minimizing adverse effects. Their application spans a wide range of conditions, offering new hope for patients unresponsive to conventional therapies. As the demand for tailored, data-driven healthcare solutions grows, NGBTs are rapidly gaining traction across global healthcare systems. By activating the body's natural mechanisms and harnessing next-gen molecular strategies, these biotherapeutics are reshaping medical treatment paradigms. With continuous R&D breakthroughs, NGBTs are advancing the possibilities of treating complex and previously untreatable diseases, offering better clinical outcomes and redefining standards in patient care.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.42 Billion
Market Size 2030	USD 10.75 Billion
CAGR 2025-2030	12.05%
Fastest Growing Segment	Oncology
Largest Market	North America

Key Market Drivers

Increasing Incidence of Cancer

The escalating global cancer burden is a major factor propelling the demand for Next Generation Biotherapeutics. Cancer rates are expected to rise by 77% by 2050 compared to 2022, highlighting an urgent need for more precise, effective treatment strategies. Traditional treatments like chemotherapy and radiation are often associated with systemic toxicity and limited efficacy. In contrast, NGBT harnesses advanced genomic profiling to tailor therapies to an individual's unique genetic profile, targeting cancer at its molecular root. These therapies are designed to overcome resistance mechanisms and minimize damage to healthy tissues, enhancing therapeutic precision and patient quality of life. As the need for more adaptable and less invasive therapies intensifies, NGBTs are positioned as a vital component in the evolving landscape of oncology treatment.

Key Market Trends

Increasing Aging Population

The global demographic shift toward an older population is a major trend fueling demand for NGBTs. By 2050, the population aged 65 and above is expected to grow to 16%, further increasing to 24% by 2100. With age comes a heightened prevalence of chronic and degenerative diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. NGBTs provide targeted, innovative therapies tailored to the complex health needs of aging individuals. These biotherapeutics offer a high level of personalization, which is especially critical for elderly patients managing multiple comorbidities. Their potential to reduce hospitalizations and long-term care needs also makes them attractive for healthcare systems aiming to improve outcomes while controlling costs. As aging continues to drive global healthcare demand, NGBTs stand out as a promising solution for personalized, effective disease management in elderly populations.

Key Market Players

Xencor, Inc.
Regenxbio & Neurimmune AG
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
AstraZeneca Plc.
F. Hoffmann-La Roche Ltd.
Kyowa Kirin Co., Ltd
Seattle Genetics, Inc
ImmunoGen, Inc
Ono Pharmaceuticals Co, Ltd

Report Scope:

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area:

Oncology
Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology:

Antibody-Drug Conjugates
Bispecific Antibodies
Antibody Fragments
Antibody-like Proteins
Others

Next Generation Biotherapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Next Generation Biotherapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
- 5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Next Generation Biotherapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapeutic Area
- 6.2.2. By Technology
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Next Generation Biotherapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapeutic Area
    - 6.3.1.2.2. By Technology
- 6.3.2. Canada Next Generation Biotherapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapeutic Area
    - 6.3.2.2.2. By Technology
- 6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapeutic Area
    - 6.3.3.2.2. By Technology

7. Europe Next Generation Biotherapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapeutic Area
- 7.2.2. By Technology
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Next Generation Biotherapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapeutic Area
    - 7.3.1.2.2. By Technology
- 7.3.2. United Kingdom Next Generation Biotherapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapeutic Area
    - 7.3.2.2.2. By Technology
- 7.3.3. Italy Next Generation Biotherapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapeutic Area
    - 7.3.3.2.2. By Technology
- 7.3.4. France Next Generation Biotherapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapeutic Area
    - 7.3.4.2.2. By Technology
- 7.3.5. Spain Next Generation Biotherapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapeutic Area
    - 7.3.5.2.2. By Technology

8. Asia-Pacific Next Generation Biotherapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapeutic Area
- 8.2.2. By Technology
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Next Generation Biotherapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapeutic Area
    - 8.3.1.2.2. By Technology
- 8.3.2. India Next Generation Biotherapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapeutic Area
    - 8.3.2.2.2. By Technology
- 8.3.3. Japan Next Generation Biotherapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapeutic Area
    - 8.3.3.2.2. By Technology
- 8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapeutic Area
    - 8.3.4.2.2. By Technology
- 8.3.5. Australia Next Generation Biotherapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapeutic Area
    - 8.3.5.2.2. By Technology

9. South America Next Generation Biotherapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapeutic Area
- 9.2.2. By Technology
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Next Generation Biotherapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapeutic Area
    - 9.3.1.2.2. By Technology
- 9.3.2. Argentina Next Generation Biotherapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapeutic Area
    - 9.3.2.2.2. By Technology
- 9.3.3. Colombia Next Generation Biotherapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapeutic Area
    - 9.3.3.2.2. By Technology

10. Middle East and Africa Next Generation Biotherapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapeutic Area
- 10.2.2. By Technology
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Next Generation Biotherapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapeutic Area
    - 10.3.1.2.2. By Technology
- 10.3.2. Saudi Arabia Next Generation Biotherapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapeutic Area
    - 10.3.2.2.2. By Technology
- 10.3.3. UAE Next Generation Biotherapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapeutic Area
    - 10.3.3.2.2. By Technology

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Next Generation Biotherapeutics Market: SWOT Analysis

14. Competitive Landscape

14.1. Xencor, Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Regenxbio & Neurimmune AG
14.3. Takeda Pharmaceutical Company Limited
14.4. Pfizer, Inc.
14.5. AstraZeneca Plc.
14.6. F. Hoffmann-La Roche Ltd.
14.7. Kyowa Kirin Co., Ltd
14.8. Seattle Genetics, Inc
14.9. ImmunoGen, Inc
14.10.Ono Pharmaceuticals Co, Ltd